Cary Street Partners Financial LLC Acquires New Holdings in AstraZeneca PLC $AZNCF

Cary Street Partners Financial LLC acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,365 shares of the company’s stock, valued at approximately $2,872,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AZNCF. L & S Advisors Inc bought a new position in AstraZeneca during the fourth quarter valued at approximately $14,863,000. Hendley & Co. Inc. bought a new position in AstraZeneca during the fourth quarter valued at approximately $11,373,000. Burling Wealth Partners LLC bought a new position in AstraZeneca during the fourth quarter valued at approximately $4,532,000. EverSource Wealth Advisors LLC bought a new position in AstraZeneca during the fourth quarter valued at approximately $1,396,000. Finally, Saranac Partners Ltd bought a new position in AstraZeneca during the third quarter valued at approximately $876,000. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Price Performance

Shares of AZNCF stock opened at $187.10 on Thursday. The company has a 50 day simple moving average of $187.10 and a two-hundred day simple moving average of $185.10. AstraZeneca PLC has a 12 month low of $122.26 and a 12 month high of $195.00.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.